Highly Focused Radiation May Curb Oligoprogression Available to Purchase

Findings from the randomized phase II CURB trial indicate that using stereotactic body radiation therapy to target oligoprogression in patients with non–small cell lung cancer significantly prolongs progression-free survival compared with standard systemic treatment. However, the same approach does not benefit patients with breast cancer.